Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2026)
Lyell Immunopharma (LYEL) posted Return on Capital Employed of 83.11% for Q1 2026, little changed sequentially from 83.0% in Q4 2025, and up 293.0% YoY from 21.15% in Q1 2025.
Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Lyell Immunopharma has reported Return on Capital Employed for 6 years, with the latest figure at 83.11% in Q1 2026.
- Quarterly Return on Capital Employed rose 293.0% year-over-year to 83.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83.11% (up 293.0% YoY) and the FY2025 annual result came in at 73.6%, down 1029.0% from the prior year.
- Return on Capital Employed was little changed at 83.11% in Q1 2026 per LYEL's latest filing, from 83.0% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.32% in Q2 2022 and troughed at 96.07% in Q2 2025.
- A 5-year average of 47.68% and a median of 34.8% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 6099 bps in 2025, then surged 293 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 20.32% in 2022, then plunged by 65 bps to 33.47% in 2023, then tumbled by 114 bps to 71.57% in 2024, then declined by 16 bps to 83.0% in 2025, then dropped by 0 bps to 83.11% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 83.11%, 83.0%, and 93.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -88.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.14% |
| Mar 31, 2026 | -83.11% |
| Dec 31, 2025 | -83.00% |
| Sep 30, 2025 | -93.99% |
| Jun 30, 2025 | -96.07% |
| Mar 31, 2025 | -86.04% |
| Dec 31, 2024 | -71.57% |
| Sep 30, 2024 | -36.00% |
| Jun 30, 2024 | -35.08% |
| Mar 31, 2024 | -34.80% |
| Dec 31, 2023 | -33.47% |
| Sep 30, 2023 | -25.93% |
| Jun 30, 2023 | -25.46% |
| Mar 31, 2023 | -20.61% |
| Dec 31, 2022 | -20.32% |
| Sep 30, 2022 | -23.18% |
| Jun 30, 2022 | -20.32% |
| Mar 31, 2022 | -21.53% |
| Dec 31, 2021 | -19.24% |
| Sep 30, 2021 | -17.90% |